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Abstract
Influenza B represents a high proportion of influenza cases in some seasons (even over
50%). The Influenza B study in General Practice (IBGP) is a multicenter study providing
information about the clinical, demographic and socio-economic characteristics of patients
affected by lab-confirmed influenza A or B. Influenza B patients and age-matched influenza
A patients were recruited within the sentinel surveillance networks of France and Turkey in
2010–11 and 2011–12 seasons. Data were collected for each patient at the swab test day,
after 9±2 days and, if not recovered, after 28±5 days. It was related to patient's characteris-
tics, symptoms at presentation, vaccination status, prescriptions of antibiotics and antivirals,
duration of illness, follow-up consultations in general practice or emergency room. We per-
formed descriptive analyses and developed a multiple regression model to investigate the
effect of patients and disease characteristics on the duration of illness. Overall, 774 influ-
enza cases were included in the study: 419 influenza B cases (209 in France and 210 in
Turkey) and 355 influenza A cases (205 in France and 150 in Turkey). There were no differ-
ences between influenza A and B patients in terms of clinical presentation and number of
consultations with a practitioner; however, the use of antivirals was higher among influenza
B patients in both countries. The average (median) reported duration of illness in the age
groups 0–14 years, 15–64 years and 65+ years was 7.4 (6), 8.7 (8) and 10.5 (9) days in
France, and 6.3 (6), 8.2 (7) and 9.2 (6) days in Turkey; it increased with age but did not differ
by virus type; increased duration of illness was associated with antibiotics prescription. In
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conclusion, our findings show that influenza B infection appears not to be milder disease
than influenza A infection.
Introduction
Influenza B represents a high proportion of all cases of influenza in some seasons (even over
50%) [1, 2], and vaccine lineage inadequacy is inevitable as two antigenically distinct influenza
B lineage (Victoria and Yamagata) cocirculate since 1985 with unpredictable predominant line-
age [3]. Thus, there is an increasing support for the use of a quadrivalent vaccine against influ-
enza, including both influenza B virus lineages [4].
The introduction of a vaccine in a health care system requires several studies, such as epide-
miological data on the incidence, healthcare utilization, case fatality and mortality impact of
the disease to be prevented in different populations and in different age groups within the same
population. Evidence on comparative epidemiology and burden of disease of influenza A and B
are important sources of information for the estimation of the public health impact [5] and to
develop cost effectiveness analysis [6] of alternative interventions, for instance the use of quad-
rivalent versus trivalent influenza vaccines.
General practice based sentinel networks provide routine surveillance which are useful to
develop real-time epidemiological study on several health conditions and diseases [7–9].
Regarding influenza, most sentinel networks collaborate with virology laboratories to confirm
the diagnosis in suspect cases [10]. Data provided by sentinel networks have already been
extensively used to plan and monitor interventions and to feed models investigating their cost
effectiveness [11].
The Influenza B study in General Practice (IBGP) is, a follow up study, aiming at providing
comparative information about the distribution of clinical, demographic and socio-economic
characteristics in patients with a laboratory confirmed diagnosis of influenza A or B. Socio-eco-
nomics results have been published elsewhere [12]. In the current paper, we present the results
of a comparison of clinical presentation and duration of illness between influenza A and B
cases in France and Turkey during 2010–2011 and 2011–2012 seasons.
The WHO recommendation for influenza vaccines for the northern hemisphere contained
the same influenza strains for both 2010–2011 and 2011–2012 seasons: an A/California/7/2009
(H1N1)-like virus; an A/Perth/16/2009 (H3N2)-like virus; a B/Brisbane/60/2008-like virus (B/
Victoria lineage) [13, 14].
Methods
Study design and selection of participants
The multicentre IBGP study performed a prospective recruitment of patients during two con-
secutive influenza seasons (from week 40 to 15): 2010–2011 (season 1) and 2011–2012 (season
2). Persons of any age with a lab confirmed diagnosis of influenza B made in the frame of estab-
lished sentinel surveillance networks in France and Turkey were eligible for inclusion into the
study.
The trigger for the study recruitment was the positive notification of an influenza B case by
the collaborating virological laboratory. This notification was sent from the laboratory to the
GP coordinators who sought to recruit the identified patient if notification occurred early
enough, i.e. before eleven days after the swab specimen had been taken for investigation. If
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more than eleven days were elapsed from the date of swabbing, the influenza B patient was not
included in the study.
For each influenza B patient included in the study, the network coordinators searched for a
correspondent influenza A patient, who has been swabbed within eleven days before and
belonged to the same age group. The following age groups were used: 0–4 (or, when possible,
0–2 and 3–4), 5–14, 15–49, 50–64 and 65+ years. An influenza A patient was then included
according to the following algorithm:
- a patient sampled by the same GP than the influenza B patient, if possible;
- a patient sampled at the same day than the influenza B patient; or, if not possible, with the
nearest date of sampling.
It was not always possible to find a suitable influenza A patient for each influenza B patient
included in the study. Therefore, some influenza B patients were matched with influenza A
patients that were identified later in the same season or in the following season. Selected influ-
enza B patients were nevertheless included in the study even though a suitable influenza A
patient could not be identified.
Sentinel surveillance networks
Established sentinel surveillance networks in France and Turkey (570 and 515 physicians,
respectively) [15, 16] participated in the IBGP study (S1 Appendix). The French network is
nationally distributed whereas in Turkey the network is based on five provinces in the western
region: Antalya, Bursa, Edirne, Istanbul and Izmir. Differently from the Turkish networks, pae-
diatricians participate in the network in France.
The sentinel physicians monitor the incidence of influenza-like illness (ILI) and/or acute
respiratory infections (ARI). In France, the GROG network adopts the wider concept of ARI
defined as sudden onset of respiratory symptom(s) with infection context (fever, headache, . . .)
in the absence of other diagnosis. In Turkey, the Ministry of Health adopts the ILI case defini-
tion of the WHO: sudden onset of fever (>38°C) with cough or sore throat, in the absence of
other diagnosis. Sentinel physicians routinely investigate, by rhino-pharyngeal swabbing, a var-
iable proportion of patients, mostly selected on an opportunistic basis, for influenza and other
respiratory viruses.
Swabbed patients represent a subset of all those presenting with an ILI/ARI syndrome
within two (in France) or three (in Turkey) days of symptoms onset. Due to the limited capac-
ity of virological analysis, practitioners were asked to swab only one or two ARI/ILI patients
each week. Combined nasal/throat swab specimens and a routine investigation request forms
(completed for each patient) were sent by post to the respective National Influenza Centre
(NIC) for virological diagnosis. In Turkey, some influenza patients were recruited in emer-
gency departments, with direct links to the influenza laboratory; for these patients postal trans-
port of specimens was not necessary.
The NICs followed the WHO collaborating centres recommendations for virus isolation,
subtyping and lineage characterization [17]. Virus detection and subtyping of influenza A and
lineage characterization of influenza B viruses were done on the samples with reverse transcrip-
tase-polymerase chain reaction (RT-PCR), which is the most sensitive available method. Vali-
dation of the testing procedures for influenza strain typing was undertaken at the WHO
Collaborating Centre for Reference and Research on Influenza of the National Institute for
Medical Research (NIMR) at Hill Mill, UK, using a ten percent sample, according to the terms
of reference of the NICs and WHO collaborating centres.
Influenza A and B Presentation and Duration France Turkey 2010-2012
PLOS ONE | DOI:10.1371/journal.pone.0139431 October 1, 2015 3 / 12
Data collection
For each patient included in the study, the data collection was performed in three moments of
the time horizon of the study: (1) at the swab test day (D0), (2) on recruitment to the study at
9 ± 2 days (D9), (3) in case the subject had not recovered by day 9, at 28 ± 5 days (D28).
At day 0, we used the virology investigation request form routinely used to collect data on:
personal details (name, month and year of birth, gender and city code), date of onset of symp-
toms, presenting symptoms and syndromes, influenza vaccination status for the current sea-
son, and prescriptions of antibiotics or antivirals. Concerning vaccination status, patients were
considered as vaccinated against the current seasonal flu if they had received at least one dose
of seasonal vaccine in the current season and if the date of vaccination preceded by at least 14
days the onset of symptoms. Patients for which the vaccination date was unknown, were con-
sidered as not vaccinated. Information about underlying conditions was based on each country
own surveillance form, which means that heterogeneous and non comparable data were col-
lected on this topic. Data were anonymised by the lab before entry into the computer database.
Further information was obtained at the time of recruitment (day 9), using a patient specific
questionnaire (illustrated by an English translation in Fig 1) completed by the sentinel physi-
cian (in France) or by the study coordinator (in Turkey) on the basis of a telephone interview.
Some potentially eligible influenza B patients were not recruited in France because: the lab
results were not transmitted to the physician in time to contact the patient within eleven days
after the swab; or the patient/GP was not reachable or did not agree to participate. Recruited
patients who were not recovered at D9 were called back at D28 using the same questionnaire.
Information was collected on: state of recovery (defined as date of return to normal activities),
number of follow-up consultations, hospital admission and emergency room visits, drug pre-
scriptions and details on sickness absence.
All information gathered during the IBGP study was stored electronically at the Clinical
Research Organization (Open Rome headquarters, Paris).
Analysis
Using data collected at day 0, 9 and 28, influenza A and B recruited patients were compared in
terms of presenting symptoms and syndromes, vaccination status, drugs taken, duration of ill-
ness (days between symptom onset and return to normal activities), number of follow-up con-
sultations, hospital admissions, days of absence from work or school. All comparisons were
made separately for France and Turkey, and further stratified by season and age group (0–14,
15–64, 65+ years). The Fisher’s exact test was used to compare the distribution of variables of
interest. A p-value was considered statistically significant when less than 0.05.
We developed a multiple regression model to investigate the effect of patients and disease
characteristics on the median duration of illness including influenza type and the other vari-
ables that were significant (p<0.05) in univariate analysis. Variables considered were: influ-
enza type, gender, age group, vaccination status, prescriptions of antibiotics and antivirals,
sickness absence (defined as reported absence at follow-up interview) and season. The regres-
sion model was fitted independently for France and Turkey, and p-values were considered as
statistically significant when less than 0.05. All analyses were performed with STATA software
(version 11).
Ethical approval and consent procedures
In France, ethical approval for the study (including consent procedures) was given by the con-
cerned national ethics committee (Comité de Protection des Personnes, Commission Consultative
Influenza A and B Presentation and Duration France Turkey 2010-2012
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sur le Traitement de l’Information en matière de recherche dans le domaine de la santé [CCTIRS]
and Commission Nationale pour l’Informatique et les Libertés [CNIL]).
All selected influenza patients (both B and A cases) were involved in a consent procedure in
two occasions: firstly in providing a swab for surveillance purpose, and then in agreeing to be
included in the study (day 9 ± 2).
Fig 1. Questionnaire for data collection at days 9 and 28 in the IBGP study. France and Turkey, 2010–
2012.
doi:10.1371/journal.pone.0139431.g001
Influenza A and B Presentation and Duration France Turkey 2010-2012
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In France, as the IBGP study does not interfere with medical intervention, verbal informed
consents were sufficient for adult participants, in accordance with the Public health code
(L1122-1 à L1122-2) [18]. For recruited children, parents provided an oral consent for the D0
swabbing and, as requested by the ethics committees, a written informed consent for the D9
contact (information letter and consent form given, or read and sent by post by the practitioner
at the D9 contact with a pre-stamped and preaddressed envelop for the return to the GP).
In the same way, in Turkey, in accordance with the Ministry of health recommendations on
standard identification and reporting system, as the IBGP study does not interfere with medical
intervention, patient or children's parents verbal informed consents are sufficient for partici-
pating and consents' record is not requested. According to the recommendation, written and
separate approval for this study were not necessary as its content was present in the routine
surveillance program [19].
Results
During the two seasons, overall 4316 influenza virus detections (among which 31.9% influenza
B) were identified within the two surveillance networks. Table 1 shows their distribution in
terms of country, season, type, subtype or lineage. The percentage of influenza B over all influ-
enza positive cases during season 1 and 2 was 48.2% and 3.6% in France and 53.6% and 24.2%
in Turkey. Concerning influenza A, 92.7% of virus detections (seasons 1 and 2 combined) were
subtyped; in both countries A(H1N1)pdm09 predominated in season 1 and A(H3N2) in sea-
son 2. Concerning influenza B, 32.0% of virus detections were characterized; the Victoria line-
age predominated in France in season 1 and in Turkey in season 2, the Yamagata lineage
predominated in Turkey in season 1, and the two lineages were equally frequent in France in
season 2.
A total of 774 patients were included in the study: 355 influenza A (205 in France and 150
in Turkey) and 419 influenza B (209 in France and 210 in Turkey) (Table 1). Males represented
53% and 49% of influenza recruits in France and Turkey, respectively. The proportion of influ-
enza B cases aged 0–14, 15–64 and 65+ years was 67%, 27% and 6% in France and 27%, 67%
and 6% in Turkey (Table 2); the age distribution of influenza A cases mirrors that of B patients,
due to matching.
In France, the profile of symptoms at presentation was similar among influenza A and B
recruits, with fever and cough being present each in>75% of patients. In Turkey, most
Table 1. Epidemic peak and type, subtype and lineage of influenza cases detected within the French and Turkish influenza surveillance networks
during 2010–2011 and 2011–2012 seasons, and (within parenthesis, in bold) included in the IBGP study.
2010–2011 2011–2012
France Turkey France Turkey
Epidemic peak (week) 5-6/2011 5/2011 7-9/2012 2-3/2012
Total inﬂuenza positives 2007 (211) 541 (206) 1495 (203) 273 (154)
Flu A (Total) 1040 (32) 251 (54) 1441 (173) 207 (96)
AH1/pdm09 831 (31) 187 (42) 63 (6) 2 (0)
AH3 100 (1) 0 (0) 1335 (164) 205 (96)
A not subtyped 109 (0) 64 (12) 43 (3) 0 (0)
Flu B (Total) 967 (179) 290 (152) 54 (30) 66 (58)
Victoria 274 (155) 0 (0) 16 (15) 53 (51)
Yamagata 18 (11) 60 (58) 19 (14) 0 (0)
B not characterized 675 (13) 230 (94) 19 (1) 13 (7)
doi:10.1371/journal.pone.0139431.t001
Influenza A and B Presentation and Duration France Turkey 2010-2012
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frequent symptoms were cough, fever, rhinitis, myalgia and headache. Very few (1%) of
recruited subjects were hospitalized in France, (no differences by influenza type) while this per-
centage was 9% in Turkey (13% of influenza B recruits vs 3% influenza A, p<0.01). The pro-
portion of recruits that were vaccinated against influenza was 5–6% in France.
In Turkey, influenza A recruits were frequently more vaccinated than influenza B recruits
(p<0.03). Antibiotics were prescribed to 26% of recruits in France and to 55% in Turkey (no
differences by influenza type). Antivirals were prescribed more frequently for influenza B than
for influenza A recruited patients in Turkey (respectively 15% vs 31%, p = 0.001) and in France
(respectively 13% vs 21%, p<0.05). In particular, the use of antiviral was higher for B than A
influenza patients in Turkey only among those aged 15–64 years (32% vs. 20%, p<0.05) and
65+ years (85% vs. 14%, p<0.01). Proportion of missing data was low (below 2%) for all
variables.
Most influenza recruited patients consulted a physician only once (Table 3). The mean num-
ber of consultations was similar for influenza A and B recruits in Turkey (respectively 1.08 and
1.04) and France (respectively 1.39 and 1.38), except among influenza B recruits aged 15–64
years in France which tend to consult more frequently (p<0.01). The number of consultations
increased with age in both influenza A and B recruited patients in France (p<0.01) but not in
Turkey.
The average (median) reported duration of illness in the age groups 0–14, 15–64 and 65
+ years was 7.4 (6), 8.7 (8) and 10.5 (9) days in France, and 6.3 (6), 8.2 (7) and 9.2 (6) days in
Table 2. Gender, age groups, presenting symptoms and syndromes, hospitalization, vaccination status and prescriptions of antibiotics and antivi-
rals among patients enrolled in the IBGP study, by country and influenza type. France and Turkey, 2010–2012.
France Turkey
Inﬂuenza A (n = 205) Inﬂuenza B (n = 209) P Inﬂuenza A (n = 150) Inﬂuenza B (n = 210) P
Gender
male 55% 50% ns 51% 48% ns
Age groups (years)
0–14 67% 67% 29% 27%
15–64 27% 27% ns 66% 67% ns
65+ 6% 6% 5% 6%
Presenting symptoms and syndromes
fever 99% 100% ns 87% 89% ns
cough 90% 92% ns 91% 95% ns
rhinitis 71% 71% ns 87% 81% ns
headache 66% 65% ns 78% 74% ns
myalgia 60% 63% ns 78% 78% ns
sore throat 56% 50% ns 45% 36% ns
dyspnea 5% 6% ns 7% 12% ns
Hospitalization
yes 1% 1% ns 3% 13% 0.002
Vaccination status
vaccinated 5% 6% ns 5% 1% 0.028
Drugs prescribed
antibiotics 28% 24% ns 51% 58% ns
antivirals 13% 21% 0.031 15% 31% 0.001
ns: not signiﬁcant
doi:10.1371/journal.pone.0139431.t002
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Turkey, with no differences by influenza type. The results of the uni- and multi-variable regres-
sion examining the impact of the variables considered on the duration of illness are given in
Table 4. In multivariable analysis, influenza type does not significantly modify the duration of
illness in either country. In both France and Turkey, the fact to be younger than 15 years (com-
pared to those aged15) was significantly associated with a reduced duration of illness while
an increased duration of illness was significantly associated with having been prescribed antibi-
otics. In Turkey, an increased duration of illness was significantly associated with having flu
during 2010–11 season in univariate, but not multiple regression analysis.
Discussion
We successfully recruited 419 influenza B and 355 influenza A laboratory confirmed cases pro-
viding a database in which we would expect to detect important differences (if any) between
influenza A and B presentation. We compared the main characteristics of influenza in two
countries (France and Turkey) during two consecutive influenza seasons (2010–11 and 2011–
12). To the best of our knowledge, this is the largest European community-based study that
compares influenza A and B in recent years. This was made possible by the fact that influenza
B circulated intensely in Europe during the 2010–2011 season [20].
We found no significant differences between influenza A and B recruited patients for most
of the aspects we considered, including presenting symptoms and syndromes, number of con-
sultations and duration of illness. We found more hospital/emergency room visits for influenza
B in Turkey though these may have been influenced by changes in healthcare access in Turkey
between the two seasons. The majority of influenza B and A cases in Turkey were respectively
enrolled during seasons 1 and 2, i.e. before and after the Turkish healthcare reform. Before the
reform in 2011, a large proportion of the population did not have any health insurance; how-
ever, free healthcare was provided in hospitals, encouraging ill people to primarily search for
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No. of consultations
(%)
once 84% 47% 46% 72% 93% 98% 100% 97%
twice 12% 39% 15% 20% 5% 1% 0% 2%
three or more times 4% 14% 39% 8% 2% 1% 0% 1%
doi:10.1371/journal.pone.0139431.t003
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hospitals. Therefore, these influenza patients were registered as hospitalized patients. After the
2011 reform, there was a stricter control on direct access of patients to the emergency rooms of
hospitals.
As shown by Irving et al. [21], no consistent difference exists in the course of disease for
patients affected by either influenza A or B. Other papers have focused on the paediatric popu-
lation [22–25], hospitalized patients [26, 27], or other specific populations [28, 29]. No consis-
tent patterns emerged that would help differentiate between influenza A and B patients solely
on the basis of their clinical presentation, except for milder symptoms among pandemic A
(H1N1) than A(H3N2) patients.
This study highlights an increased duration of illness significantly associated with having
been prescribed antibiotics, in both France and Turkey, probably because antibiotics are usu-
ally prescribed when influenza clinical pattern is severer or followed by bacterial infections.
Campaigns against inappropriate prescription of antibiotics in patients with ARI were con-
ducted in France but not in Turkey in recent years; thus the higher proportion of antibiotics
prescription in the latter was not surprising. Likewise, health authorities in France published
recommendations for antivirals prescription, specifying that it should be only given to ARI
patients characterized as clinically severe (i.e. with complications) or having specific risk factors
(i.e. diabetes) [30]. Antivirals were more frequently prescribed in influenza B cases compared
to A cases in our study. This could be explained by the fact that influenza B cases were mostly
recruited during 2010–2011 season (post pandemic season with intense circulation of A
(H1N1)pdm09) whereas influenza A cases were mostly recruited during 2011–2012 season.
The low proportion of patients that were vaccinated against influenza in our study sample
may be partly explained by the low coverage rate of healthy children and adults in France and
Table 4. Uni- andmulti-variable regression analysis of variables impacting on duration of illness. France and Turkey, 2010–2012.
Univariate analysis Logistic multi-variable analysis
Covariate Kolmogorov-Smirnov p-value Odd Ratio 95% CI p-value
France
Male gender 0.137
Age <15 years 0.000 0.56 0.37 0.85 0.007
Age  65 years 0.062
Inﬂuenza B 0.348
Season 2010–11 0.261
Vaccination against inﬂuenza 0.678
Antivirals prescribed 0.711




Age <15 years 0.005 0.43 0.27 0.71 0.001
Age  65 years 0.459
Inﬂuenza B 0.423
Season 2010–11 0.000 0.76 0.49 1.20 0.241
Vaccination against inﬂuenza 0.559
Antivirals prescribed 0.537
Antibiotics prescribed 0.006 2.12 1.38 3.27 0.001
Sickness absence 0.204
doi:10.1371/journal.pone.0139431.t004
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Turkey [31, 32] and by the effectiveness, although not perfect, of the influenza vaccination
among the elderly. Both in France and Turkey, an increased duration of illness is described
among elderly patients, emphasizing that they are more exposed to more severe clinical
patterns.
The limitations of our study are mainly due to sentinel surveillance peculiarities. There were
inevitable delays in the surveillance program to get the virological result, including the delays
between illness onset and consultation in which the patient is swabbed; postal transit of swab
test/form from medical office to laboratory; completion of virological investigation and trans-
mission of result to sentinel physician; physician receipt of result and effective telephone con-
tact with eligible patient within the recruitment time window. These delays strongly limited
eligible patients’ recruitment to the follow-up study.
Sampling or virological analysis bias may occur. However, it is not part of the routine sur-
veillance to investigate every ILI/ARI patient, because of work load and costs constraints that
limit the laboratory investigation. In the same way, the virological investigation would ideally
include strain subtyping and lineage characterization of all samples but these are not under-
taken routinely. As influenza A and B cases were matched by age, we could not compare the
age distribution between the two influenza types. The limitations on recruitment to follow-up
limited the opportunity for meaningful secondary analyses such as separate analysis by co-
morbidity. The discretion left to participating practitioners in sampling the ARI/ILI patients
may introduce a sampling bias and distort some results, for instance those on the clinical pre-
sentation and the proportion of vaccinated. Recall bias may be also an issue, as some informa-
tion was collected long time after the onset of symptoms.
Differences in access to healthcare between France and Turkey especially concerning the
care of children limited opportunities for comparing the results in the two countries. The
national differences and distinct arrangements for routine surveillance limited the use of
pooled analyses where less objective clinical outcome diagnoses are compared. These practical
limitations need to be addressed when planning similar studies.
In conclusion, we showed in two distinct settings that the presentation and the duration of
illness due to influenza B do not differ from influenza A. Influenza B is not a milder disease
than influenza A and, although it is (on average) less frequent than the latter, the efforts aiming
at reducing its burden of disease should be as great as possible. Several differences were instead
observed between influenza patients in France and Turkey, which most likely depend on the
large dissimilarities in the healthcare systems between these two countries. This raises doubts
about the comparability of studies that, unlike the IBGP, are conducted in different countries
applying differently the same study protocol.
Supporting Information
S1 Appendix. Influenza surveillance network in France and Turkey.
(DOCX)
Acknowledgments
We acknowledge Peter Spreeuwenberg for his help in multilevel regression analysis. The IBGP
study team is composed of all authors and the following persons: Vanessa Escuret, Microbiol-
ogy Laboratory, University of Lyon 1, Lyon, France; Sylvie Behilil, Virology Department, Unit
of Molecular Genetics of RNA viruses, National Influenza Center, Pasteur Institute, CNRS
UMR3569, Université Paris Diderot Sorbonne Paris Cité, Paris, France; Tan Tai Bui and Elodie
Nauleau, Open Rome (Organize and Promote Epidemiological Network), Paris, France; the
Influenza A and B Presentation and Duration France Turkey 2010-2012
PLOS ONE | DOI:10.1371/journal.pone.0139431 October 1, 2015 10 / 12
practitioners of the sentinel networks, Réseau des GROG, Paris, France, and BGGB network in
Turkey. Jean Marie Cohen is the lead author of the IBGP study team (jmcoco@openrome.org).
Author Contributions
Conceived and designed the experiments: JMC GM JP DMF. Performed the experiments: JMC
MLS MC AM IDMV VE. Analyzed the data: JMCMLS AM ID. Contributed reagents/materi-
als/analysis tools: MV VE MC SB. Wrote the paper: JMC SC AM ID JP DMF.
References
1. Meijer A, Meerhoff TJ, Meuwissen LE, van der Velden J, Paget WJ, European Influenza Surveillance
Scheme. Epidemiological and virological assessment of influenza activity in Europe during the winter
2005–2006. Euro Surveill. 2007; 12(9):E11–2. PMID: 17991413
2. Grant KA, Carville K, Fielding JE, Barr IG, Riddell MA, Tran T, et al. High proportion of influenza B char-
acterises the 2008 influenza season in Victoria. Commun Dis Intell Q Rep. 2009; 33(3): 328–36. PMID:
20043604
3. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother.
2012; 8(1): 81–8. doi: 10.4161/hv.8.1.17623 PMID: 22252006
4. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine. 2010; 28 Suppl 4:
D45–53. doi: 10.1016/j.vaccine.2010.08.028 PMID: 20713260
5. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a
quadrivalent seasonal influenza vaccine. Vaccine. 2012; 30(11):1993–8. doi: 10.1016/j.vaccine.2011.
12.098 PMID: 22226861
6. Pitman RJ, Nagy LD, Antonova E, Scott DA. Cost-Effectiveness Comparison Of Quadrivalent Versus
Trivalent Influenza Vaccines In The United States. Value in Health. 2013; 16(3):A90.
7. Truyers C, Lesaffre E, Bartholomeeusen S, Aertgeerts B, Snacken R, Brochier B, et al. Computerized
general practice based networks yield comparable performance with sentinel data in monitoring epide-
miological time-course of influenza-like illness and acute respiratory illness. BMC Fam Pract. 2010;
11:24. doi: 10.1186/1471-2296-11-24 PMID: 20307266
8. Pérez-Farinós N, Ordobás M, García-Fernández C, García-Comas L, Cañellas S, Rodero I, et al. Vari-
cella and herpes zoster in Madrid, based on the Sentinel General Practitioner Network: 1997–2004.
BMC Infect Dis. 2007; 7:59. PMID: 17570859
9. Van den Block L, Van Casteren V, Deschepper R, Bossuyt N, Drieskens K, Bauwens S, et al. Nation-
wide monitoring of end-of-life care via the Sentinel Network of General Practitioners in Belgium: the
research protocol of the SENTI-MELC study. BMC Palliat Care. 2007; 6:6. PMID: 17922893
10. Hardelid P, Fleming DM, Andrews N, Barley M, Durnall H, Mangtani P, et al. Effectiveness of trivalent
and pandemic influenza vaccines in England andWales 2008–2010: results from a cohort study in gen-
eral practice. Vaccine. 2012; 30(7): 1371–8. doi: 10.1016/j.vaccine.2011.12.038 PMID: 22178524
11. RozenbaumMH, van Hoek AJ, Fleming D, Trotter CL, Miller E, EdmundsWJ. Vaccination of risk
groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ.
2012; 345: e6879. doi: 10.1136/bmj.e6879 PMID: 23103369
12. Silva ML, Perrier L, Späth HM, Grog I, Mosnier A, Havet N, et al. Economic burden of seasonal influ-
enza B in France during winter 2010–2011. BMC Public Health. 2014; 14:56. doi: 10.1186/1471-2458-
14-56 PMID: 24443900
13. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in
the 2010–2011 northern hemisphere influenza season. Available: http://www.who.int/influenza/
vaccines/virus/recommendations/201002_Recommendation.pdf. Accessed 29 July 2013.
14. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in
the 2011–2012 northern hemisphere influenza season. Available: http://www.who.int/influenza/
vaccines/2011_02_recommendation.pdf. Accessed 29 July 2013.
15. Hannoun C, DabW, Cohen JM. A new influenza surveillance system in France: the Ile-de-France
"GROG". 1. Principles and methodology. Eur J Epidemiol. 1989; 5(3): 285–93. PMID: 2792306
16. Ciblak MA, HasoksuzM, Escuret V, Valette M, Gul F, Yilmaz H, et al. Surveillance and oseltamivir resis-
tance of human influenza a virus in Turkey during the 2007–2008 season. J Med Virol. 2009; 81(9):
1645–51. doi: 10.1002/jmv.21546 PMID: 19626608
17. World Health Organization (WHO). WHO Information for the molecular diagnosis of influenza virus in
humans—update (August 2011). Available: http://www.who.int/influenza/resources/documents/
molecular_diagnosis_influenza_virus_humans_update_201108.pdf. Accessed 29 July 2013.
Influenza A and B Presentation and Duration France Turkey 2010-2012
PLOS ONE | DOI:10.1371/journal.pone.0139431 October 1, 2015 11 / 12
18. French Code of Public Health. Articles L1122-1 and L1122-2. Available: http://www.legifrance.gouv.fr/.
Accessed 24 January 2014.
19. General Directorate of Primary Health Care. Notification of infectious diseases-Standard identification
and reporting system, surveillance and laboratory guide. Turkish Ministry of Health, Ankara. 4th edi-
tion. 2005.
20. European Centre for Disease Prevention and Control. Annual Epidemiological Report 2012. Reporting
on 2010 surveillance data and 2011 epidemic intelligence data. Stockholm: ECDC.
21. Irving SA, Patel DC, Kieke BA, Donahue JG, Vandermause MF, Shay DK, et al. Comparison of clinical
features and outcomes of medically attended influenza A and influenza B in a defined population over
four seasons: 2004–2005 through 2007–2008. Influenza Other Respir Viruses. 2012; 6(1):37–43. doi:
10.1111/j.1750-2659.2011.00263.x PMID: 21668663
22. Daley AJ, Nallusamy R, Isaacs D. Comparison of influenza A and influenza B virus infection in hospital-
ized children. J Paediatr Child Health. 2000; 36(4):332–5. PMID: 10940165
23. Chiu SS, Chan KH, Chen H, Young BW, LimW,WongWH, et al. Virologically confirmed population-
based burden of hospitalization caused by influenza A and B among children in Hong Kong. Clin Infect
Dis. 2009; 49(7):1016–21. doi: 10.1086/605570 PMID: 19722912
24. Esposito S, Molteni CG, Daleno C, Valzano A, Fossali E, Da Dalt L, et al. Clinical and socioeconomic
impact of different types and subtypes of seasonal influenza viruses in children during influenza sea-
sons 2007/2008 and 2008/2009. BMC Infect Dis. 2011; 11:271. doi: 10.1186/1471-2334-11-271 PMID:
21992699
25. Nitsch-Osuch A, Wozniak-Kosek A, Korzeniewski K, Zycinska K, Wardyn K, Brydak LB. Clinical fea-
tures and outcomes of influenza A and B infections in children. Adv Exp Med Biol. 2013; 788:89–96.
doi: 10.1007/978-94-007-6627-3_14 PMID: 23835964
26. Wie SH, So BH, Song JY, Cheong HJ, Seo YB, Choi SH, et al. A comparison of the clinical and epide-
miological characteristics of adult patients with laboratory-confirmed influenza A or B during the 2011–
2012 influenza season in Korea: a multi-center study. PLoS One. 2013; 8(5): e62685. doi: 10.1371/
journal.pone.0062685 PMID: 23671624
27. Cohen AL, Hellferscee O, Pretorius M, Treurnicht F, Walaza S, Madhi S, et al. Epidemiology of influ-
enza virus types and subtypes in South Africa, 2009–2012. Emerg Infect Dis. 2014; 20(7):1162–9. doi:
10.3201/eid2007.131869 PMID: 24960314
28. Yap J, Tan CH, Cook AR, Loh JP, Tambyah PA, Tan BH, et al. Differing clinical characteristics between
influenza strains among young healthy adults in the tropics. BMC Infect Dis. 2012; 12:12. doi: 10.1186/
1471-2334-12-12 PMID: 22264216
29. Hayward AC, Fragaszy EB, Bermingham A, Wang L, Copas A, EdmundsWJ, et al. Comparative com-
munity burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study.
Lancet Respir Med. 2014; 2(6):445–54. doi: 10.1016/S2213-2600(14)70034-7 PMID: 24717637
30. Public Health Council. Antivirals use during circulation of the A(H1N1)pdm09 virus [in French]. Avail-
able: http://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=243. Accessed 17 July 2015.
31. Influenza Expertise and Information Group [in French]. Available: http://www.grippe-geig.com/webapp/
website/website.html?id=2535762. Accessed 17 July 2015.
32. Ciblak MA; Grip Platformu. Influenza vaccination in Turkey: prevalence of risk groups, current vaccina-
tion status, factors influencing vaccine uptake and steps taken to increase vaccination rate. Vaccine.
2013; 31(3):518–23. doi: 10.1016/j.vaccine.2012.11.022 PMID: 23174194
Influenza A and B Presentation and Duration France Turkey 2010-2012
PLOS ONE | DOI:10.1371/journal.pone.0139431 October 1, 2015 12 / 12
